JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2011, 60(3):110-115

Clinical significance of cytochrome P450 genetic polymorphism - Part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2

Jana Ďuricová*, Milan Grundmann
Ostravská Univerzita v Ostravě, Lékařská fakulta, Ústav klinické farmakologie FN

Inter-individual variability in drug response is a major clinical problem. Much of the variability has been observed in drug metabolism, particularly in the enzymes of cytochrome P450. Genetic polymorphism in these enzymes may influence a patient's response to commonly prescribed drugs. The first part of this review describes the enzymatic system of cytochrome P450 and further focuses on the influence of genetic polymorphism of cytochrome P450 1A2 on drug effect.

Keywords: cytochrome P450; genetic polymorphism; CYP1A2

Received: January 31, 2011; Accepted: April 11, 2011; Published: March 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ďuricová J, Grundmann M. Clinical significance of cytochrome P450 genetic polymorphism - Part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2. Čes. slov. farm. 2011;60(3):110-115.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gonzalez, F. J., Gelboin, H. V.: Human Cytochrome P450: Evolution and cDNA-directed expression. Environ. Health Perspect. 1992; 98, 81-85. Go to original source... Go to PubMed...
    2. Omiecinski, C. J., Remmel, R. P., Hosagrahara, V.P.: Concise review of the cytochrome P450s and their roles in toxicology. Toxicol. Sci. 1999; 48, 151-156. Go to original source... Go to PubMed...
    3. Chang, G. W., Kam, P. C.: The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia 1999; 54, 42-50. Go to original source... Go to PubMed...
    4. Anzenbacher, P, Anzenbacherová, E.: Cytochromes P450 and metabolism of xenobiotics. Cell. Mol. Life. Sci. 2001; 58, 737-747. Go to original source... Go to PubMed...
    5. Guengerich, F. P.: Cytochrome P450: What have we learned and what are the future issues? Drug. Metab. Rev. 2004; 36, 159-197. Go to original source... Go to PubMed...
    6. Soucek, P., Gut, I.: Co je to cytochrom P 450? Enzymatické formy cytochromu P450 - dosažený stupeň znalostí. Cas. Lek. Cesk. 1993; 12, 353-358.
    7. Guengerich, F. P.: Cytochromes P450, drugs and diseases. Mol. Interv. 2003; 3, 194-204. Go to original source... Go to PubMed...
    8. Guengerich, F. P.: Cytochrome P450s and other enzymes in drug metabolism and toxicity. The APPS J. 2006; 8, E101-110. Go to original source... Go to PubMed...
    9. Guengerich, F. P.: Update information on human P450s. Drug. Metab. Rev. 2002; 34, 7-15. Go to original source... Go to PubMed...
    10. Güzey, C., Spigset, O.: Genotyping as a tool to predict adverse drug reactions. Curr. TP. Med. Chem. 2004; 4, 1411-1421. Go to original source... Go to PubMed...
    11. Rogers, J. F., Nafzinger, A. N., Bertino, J. S.: Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450 - metabolized drugs. Am. J. Med. 2002; 113, 746-750. Go to original source... Go to PubMed...
    12. Buzková, H., Pechandová, K., Slanař, O., Perlík, F.: Genetic polymorphism of cytochrome P450 and methods for its determination. Prague. Med. Rep. 2006; 107: 383-393.
    13. Dahl, M. L.: Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics. Useful aid to Prescribing? Clin. Pharmacokinet. 2002; 41, 453-470. Go to original source... Go to PubMed...
    14. Home page of the human cytochrome P450 (CYP 2D6) allele nomenclature (updated 2010 July 20). Available from: http://www.cypalleles.ki.se/cyp2d6.htm
    15. Bertilsson, L.: Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet. 1995; 29, 192-209. Go to original source... Go to PubMed...
    16. Ingelman-Sundberg, M.: Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends. Pharmacol. Sci. 2004; 25, 193-200. Go to original source... Go to PubMed...
    17. Pirmohamed, M., Park, B. K.: Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003; 192, 23-32. Go to original source... Go to PubMed...
    18. Steiner, E., Iselius, L., Alván, G., Lindsten, J., Sjöqvist, F.: A family study of genetic and environmental factors determing polymorphic hydroxylation of debrisoquin. Clin. Pharmacol. Ther. 1985; 38, 394-401. Go to original source... Go to PubMed...
    19. Aklillu, E., Herrlin, K., Gustafsson, L. L., Bertilsson, L., Ingelman-Sundberg, M.: Evidence for environmental influence on CYP2D6-cataysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living or in Sweden. Pharmacogenetics 2002; 12, 375-383. Go to original source... Go to PubMed...
    20. Wolbold, R., Klein, K., Burk, O., Nüssler, A. K., Neuhaus, P., Eichelbaum, M., Schwab, M., Zanger, U. M.: Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003; 38, 978-988. Go to original source...
    21. Villeneuve, J. P., Pichette, V.: Cytochrome P450 and liver diseases. Curr. Drug. Metab. 2004; 5, 273-282. Go to original source... Go to PubMed...
    22. Tracy, T. S., Venkataramanan, R., Glover, D., Caritis, S. N.: Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A4 activity) during pregnancy. Am J Obstet. Gynecol. 2005; 192, 633-639. Go to original source... Go to PubMed...
    23. Schaffer, S. D., Yoon, S., Zadezensky, I.: A review of smoking cessation: potentially risky effects on prescribed medications. J. Clin. Nurs. 2009; 18, 1533-1540. Go to original source... Go to PubMed...
    24. Nekvidová, J., Anzenbacher, P.: Interactions of food and dietary supplements with drug metabolising cytochrome P450 enzymes. Ces slov. Farm. 2007; 56, 165-173.
    25. Guengerich, F. P.: Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. Am. J. Clin. Nutr. 1995; 61, 651-658. Go to original source... Go to PubMed...
    26. Tanaka E., Hisawa S.: Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J. Clin. Pharm. Ther. 1999; 24, 7-16. Go to original source... Go to PubMed...
    27. Perucca, E.: Clinically relevant drug interactions with antiepileptic drugs. Br. J. Clin. Pharmacol. 2005; 61, 246-255. Go to original source... Go to PubMed...
    28. Jain, K. K.: Applications of AmpliChip CYP450. Mol. Diagn. 2005; 9, 119-127. Go to original source...
    29. Pucci, L., Geppetti, A., Maggini, V., Lucchesi, D., Maria Rossi A., Longo V.: CYP1A2 F21L and F186L polymorphisms in an Italian population sample. Drug Metab. Pharmacokinet. 2007; 22, 220-222. Go to original source... Go to PubMed...
    30. Ghotbi, R., Christensen, M., Roh, H., Ingelman-Sundberg M., Aklillu E, Bertilsson L.: Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur. J. Clin. Pharmacol. 2007; 63, 537-546. Go to original source... Go to PubMed...
    31. Sachse, C., Brockmöller, J., Bauer, S., Roots, I.: Functional signifance of a C→A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 1999; 47, 445-449. Go to original source... Go to PubMed...
    32. Nakajima, M., Yokoi, T., Mizutani, M., Kinoshita, M., Funayama, M., Kamataki, T.: Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. 1999;125, 803-808. Go to original source... Go to PubMed...
    33. Aklillu, E., Carrillo, J. A., Makonnen, E., Hellman K., Pitarque M., Bertilsson L., Ingelman-Sundberg M.: Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol. Pharmacol. 2003; 64, 659-69. Go to original source... Go to PubMed...
    34. Relling, M. V., Lin, J. S., Ayers, G. D., Evans, W. E.: Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A activities. Clin. Pharmacol. Ther. 1992; 52, 643-658. Go to original source... Go to PubMed...
    35. Zhou, S. F., Yang, L. P., Zhou, Z. W., Liu, Y. H., Chan, E.: Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009; 11: 481-494. Go to original source... Go to PubMed...
    36. Uslu, A., Ogus, C., Ozdemir, T., Bilgen, T., Tosun, O., Keser, I.: The effect of CYP1A2 gene polymorphism on Theophylline metabolism and chronic obstructive pulmonary disease in Turkish patients. BMB Rep. 2010; 43, 530-534. Go to original source...
    37. Obase, Y, Shimoda, T, Kawano, T, Saeki, S., Tomari, S. Y., Mitsuta-Izaki, K., Matsuse, H., Kinoshita, M., Kohno, S.: Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with astma. Clin. Pharmacol. Ther. 2003; 73, 468-474. Go to original source... Go to PubMed...
    38. Eap, C. B., Bender.S, Jaquenoud Sirot, E., Cucchia, G., Jonzier-Perey, M., Baumann, P., Allorge, D., Broly, F.: Nonresponse to clozapine and ultrarapid CYP1A2 activity: Clinical data and analysis of CYP1A2 gene. J. Clin. Psychopharmacol. 2004; 24, 214-219. Go to original source... Go to PubMed...
    39. Ozdemir, V., Kalow, W., Okey, A. B., Lam, M. S., Albers, L. J., Reist, C., Fourie, J., Posner, P., Collins, E. J., Roy, R.: Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C→A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J. Clin. Psychopharmacol. 2001; 21, 603-606. Go to original source... Go to PubMed...
    40. Bondolfi G., Morel F., Crettol S., Rachid F., Baumann P., Eap C. B.: Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther. Drug. Monit. 2005; 27, 539-543. Go to original source... Go to PubMed...
    41. Jaquenoud Sirot, E., Knezevic, B., Morena, G. P., Harenberg, S., Oneda, B., Crettol, S., Ansermot, N., Baumann, P., Eap, C. B.: ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J. Clin. Psychopharmacol. 2009; 29, 319-326. Go to original source... Go to PubMed...
    42. Kootstra-Ros, J. E., Smallegoor, W., van der Weide, J.: The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann. Clin. Biochem. 2005; 42, 216-219. Go to original source... Go to PubMed...
    43. Laika, B., Leucht, S., Heres, S., Schneider, H., Steimer, W.: Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J. 2010; 10, 20-29. Go to original source... Go to PubMed...
    44. Shirley, K. L., Hon, Y. Y., Penzak, S. R., Lam, Y. W., Spratlin, V., Jann, M. W.: Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology 2003; 28, 961-966. Go to original source... Go to PubMed...
    45. Bohanec Grabar, P., Rozman, B., Tomsic, M., Suput, D., Logar, D., Dolzan, V.: Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur. J. Clin. Pharmacol. 2008; 64, 871-876. Go to original source... Go to PubMed...
    46. Fuhr, U., Rost, K. L.: Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994; 4, 109-116. Go to original source... Go to PubMed...
    47. Palatini, P., Ceolotto, G., Ragazzo, F., Dorigatti, F., Saladini, F., Papparella, I., Mos, L., Zanata, G., Santonastaso, M.: CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J. Hypertens. 2009; 27, 1594-1601. Go to original source... Go to PubMed...
    48. Cornelis, M. C., El-Sohemy, A., Kabagambe, E. K., Campos, H.: Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006; 295, 1135-1141. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.